1
Home
Companies

Aprea Therapeutics

#9985

Rank

$13.48M

Marketcap

US United States

Country

Aprea Therapeutics
Leadership team

Mr. Christian S. Schade (Chairman & CEO)

Dr. Oren Gilad Ph.D. (Co-Founder, Pres & Director)

Mr. Scott M. Coiante (Sr. VP, CFO & Sec.)

Products/ Services
Biotechnology, Health Care, Medical, Personal Health, Pharmaceutical
Headquarters
Stockholm, Stockholms Lan, Sweden
Established
2003
Company Registration
SEC CIK number: 0001781983
Traded as
APRE
Social Media
URL
https://atrinpharma.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
History

Aprea Therapeutics was founded in 2008 with a mission to develop anticancer compounds that specifically target tumor suppressing proteins. The company has since established strong relationships with renowned global research institutes and has signed strategic collaborations with several cardiovascular and oncology drug-focused partners.

Mission
At Aprea Therapeutics, our mission is to bring novel and effective anticancer compounds to patients who need them, in order to improve quality of life, extend survival and reduce the risk of relapse.
Vision
Our vision is to become a leader in the development and commercialization of innovative cancer therapies, and to bring meaningful therapeutic options to those battling cancer.
Key Team

Mr. Hank Breslin (Head of Medicinal Chemistry)

Dr. Gregory A. Korbel Ph.D. (Sr. VP & COO)

Dr. Rifat Pamukcu M.D. (Chief Medical Advisor & Director)

Dr. Dansu Li Ph.D. (Head of Technology)

Ms. Andrea Epstein (Controller)

Dr. Lars B. Abrahmsen Ph.D. (Sr. VP & Chief Scientific Officer)

Dr. Michel Afargan Ph.D. (Head of Pharmacology Devel.)

Recognition and Awards
Aprea Therapeutics has been recognized with several awards and accolades, such as the Red Herring Global Top 100 Award, Frost & Sullivan New Product Innovation Award, AACC InnoStars Award, and a European Milestone Award.
References

https://in.investing.com/equities/aprea-therapeutics-inc

https://finance.yahoo.com/quote/APRE/profile?p=APRE

https://www.crunchbase.com/organization/aprea-ab

https://companiesmarketcap.com/

https://atrinpharma.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Aprea Therapeutics
Leadership team

Mr. Christian S. Schade (Chairman & CEO)

Dr. Oren Gilad Ph.D. (Co-Founder, Pres & Director)

Mr. Scott M. Coiante (Sr. VP, CFO & Sec.)

Products/ Services
Biotechnology, Health Care, Medical, Personal Health, Pharmaceutical
Headquarters
Stockholm, Stockholms Lan, Sweden
Established
2003
Company Registration
SEC CIK number: 0001781983
Traded as
APRE
Social Media
URL
https://atrinpharma.com